西酞普兰与阿米替林治疗脑卒中后抑郁的对照研究

目的评价西酞普兰治疗脑卒中后抑郁的疗效及安全性。方法将50例符合CCMD-3诊断标准的脑卒中后抑郁的患者随机分为西酞普兰组和阿米替林组，各25例，疗程8周，用汉密尔顿抑郁量表（HAMD）及副反应量表（TESS）评定疗效和副反应。结果两组总体疗效相似，西酞普兰组在1周末时HAMD评分及减分率较阿米替林组有显著差异，说明西酞普兰组起效较快，且副反应轻。结论西酞普兰治疗脑卒中后抑郁安全有效。     

西酞普兰治疗脑卒中后抑郁临床观察

目的：评价西酞普兰治疗脑卒中后抑郁的疗效和不良反应。方法：采用西酞普兰与阿米替林对42例脑卒中后抑郁患者进行8周双盲对照治疗。用汉密尔顿抑郁量表(HAMD)、临床疗效总评量表病情严重程度(CGI-SI)、副反应量表(TESS)评定疗效及不良反应。结果：西酞普兰与阿米替林疗效相近，但西酞普兰起效快，不良反应少。结论：西酞普兰治疗脑卒中后抑郁安全有效。     

西酞普兰治疗脑卒中后抑郁对照研究

目的：比较西酞普兰与阿米替林治疗脑卒中后抑郁的疗效和安全性。方法：72例脑卒中后抑郁患者，随机分成两组，分别用西酞普兰和阿米替林治疗8周。采用汉密顿抑郁量表(HAMD)、Montgomerg-Asberg抑郁量表(MADS)和副反应量表(TESS)于治疗前和治疗后1、2、4、8周末分别评定疗效和不良反应。结果：西酞普兰组与阿米替林组间的HAMD、MADS评分差异均无显著性，西酞普兰组不良反应较阿米替林组少而轻。结论：西酞普兰治疗脑卒中后抑郁疗效好，安全性高，不良反应轻微。     

西酞普兰治疗老年脑卒中后抑郁临床对照研究

目的探讨西酞普兰治疗老年抑郁症的临床疗效和安全性。方法将40例老年脑卒中后抑郁患者随机分为两组,分别给予西酞普兰和阿米替林治疗,共6周,采用汉密顿抑郁量表(HAMD)、副反应量表(TESS)于治疗前和治疗1、2、4、6周末分别评定疗效及不良反应。结果西酞普兰和阿米替林治疗老年脑卒中后抑郁的疗效相似,但西酞普兰比阿米替林起效快,不良反应轻,疗效指数优于阿米替林(P<0.05)。结论西酞普兰可作为治疗老年脑卒中后抑郁的首选药物。     

西酞普兰与阿米替林治疗抑郁症对照研究

为探讨西酞普兰治疗抑郁症的疗效和不良反应，我们用西酞普兰治疗抑郁症并与阿米替林进行对照研究，现将结果报告如下。     

西酞普兰治疗脑卒中后抑郁障碍的对照分析

目的比较西酞普兰和阿米替林对脑卒中后抑郁障碍的疗效及神经功能康复的影响。方法62例患者随机分为西酞普兰组和阿米替林组,治疗6周采有汉密尔顿抑郁量表(HAMD)评定疗效。结果西酞普兰组在2~4周末时对脑卒中后抑郁障碍的疗效明显优于阿米替林组,在6周末时两者无明显差异,且西酞普兰组不良反应更少。结论西酞普兰可明显改善脑卒中后抑郁障碍的程度。     

西酞普兰与阿米替林治疗抑郁症的临床疗效对照分析

目的 探讨西酞普兰对抑郁症的临床疗效及安全性。方法将46例抑郁症患者随机分配至西酞普兰组及阿米替林组(各23例)。西酞普兰治疗剂量为20～40mg／，1次／d，阿米替林为150-300mg／，1次／d。观察时间均为6周。疗效评定采用Hamilton抑郁量表(HAMD)。安全性评价应用TESS、实验室检查及体查。结果西酞普兰组显效率为74％，有效率为91％，与阿米替林组的65％及87％相当；西酞普兰组不良反应较阿米替林组少且轻微，患者依从性好。结论西酞普兰与阿米替林对抑郁症均有较好的疗效，但西酞普兰具有日服剂量小、给药方法简便、不良反应轻微等优点。     

西酞普兰与阿米替林治疗产后抑郁症对照研究

对产后抑郁症患者用西酞普兰进行对照治疗。1对象和方法为2002年10月至2005年5月在我院女病区住院的患者,符合中国精神障碍分类与诊断标准第3版抑郁发作诊断标准;Hamilton抑郁量表(HAMD)≥17分;产后4～120d;排除严重躯体疾病。共36例,按顺序用随机表单双数分为西酞普兰组及阿米     

西酞普兰与阿米替林治疗抑郁症的对照研究

目的比较西酞普兰与阿米替林治疗抑郁症的疗效与副反应。方法80例抑郁症随机分成两组,一组服用西酞普兰,另一组服用阿米替林,治疗8周。结果西酞普兰组显效率为82.5%,总有效率95%;阿米替林组显效率为67.5%,总有效率92.5%。起效时间:西酞普兰为11天,平均(13.4±2.6)天。阿米替林为15天,平均(16.2±2.1)天。西酞普兰组和阿米替林组的副反应发生率分别为12.5%和47.5%,差异有显著性(p〈0.01)。结论西酞普兰治疗抑郁症疗效确切,起效快,副反应小,安全性大,可作为一线抗抑郁药物。     

西酞普兰与阿米替林治疗抑郁症的对照研究

目的　探讨选择性五羟色胺再摄取抑制剂西酞普兰治疗抑郁症的疗效及安全性。方法　将 6 0例符合CCMD 3诊断标准的抑郁症患者随机分为两组 ,分别给予西酞普兰和阿米替林治疗 ,共治疗 6周。采用汉密尔顿抑郁量表 (HAMD)、汉密尔顿焦虑量表 (HAMA)、临床总体评定量表 (CGI)评定临床疗效 ,采用副反应量表 (TESS)评定副反应。结果　西酞普兰组显效率 80 % ,阿米替林组显效率 76 .6 7% ,差异无显著性 ,各因子分中西酞普兰组认知障碍减分多于阿米替林组 ,差异有显著性。HAMA减分西酞普兰组少于阿米替林组 ,差异无显著性。西酞普兰常见副反应有恶心、口干、头痛等 ,但比较轻微。结论　西酞普兰见效快 ,疗效肯定 ,副反应发生率少而轻微。     

西酞普兰治疗老年期抑郁症疗效观察

目的：探讨西酞普兰治疗老年期抑郁症的临床疗效及安全性.方法：将60例老年期抑郁症患者随机分为西酞普兰组及阿米替林组（各30例）.西酞普兰治疗剂量为20～40 mg/d,阿米替林为100～250 mg/d.疗程6周.疗效评定采用Hamilton抑郁量表（HAMD）,安全性评价应用副反应量表（TESS）及实验室检查.结果：西酞普兰组显效率为77%,有效率为92%,与阿米替林组的70%及90%相当;西酞普兰组不良反应较阿米替林组少且轻微.结论：西酞普兰与阿米替林对老年期抑郁症均有较好的疗效,但西酞普兰具有服用简便,不良反应轻等优点.     

西酞普兰治疗阿尔茨海默病所致抑郁对照研究

目的:比较西酞普兰与阿米替林治疗阿尔茨海默病(AD)所致抑郁的患者临床疗效和安全性.方法:80例诊断为AD的抑郁患者,随机分成两组,分别用西酞普兰和阿米替林治疗8周.采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)于治疗前和治疗2、4、6、8周末分别评定疗效和不良反应.结果:西酞普兰组与阿米替林组HAMD评分差异无显著性.西酞普兰组不良反应较阿米替林组少而轻.结论:西酞普兰治疗阿尔茨海默病的抑郁疗效好,安全性高,不良反应轻微.     

A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients

In a controlled, clinical, multicentre trial comprising a total of 43 patients (17 men and 26 women) citalopram was compared double-blindly with amitriptyline. Nineteen patients of each group were classified as endogeneously depressed, whereas four patients of the citalopram group and one of the amitriptyline group were classified as non-endogenously depressed. The patients were seriously ill with a high frequency of previous depressive episodes and of mental disorders among their closest relatives. Thirteen of the patients in either group had received antidepressants without satisfactory effect before entry into the trial. Each patient was treated for a period of at least 3 weeks with daily citalopram doses of 30-60 mg or daily amitriptyline doses of 75-225 mg. A statistically significant reduction of MADRS scores (total scores as well as each of the 10 individual items) was recorded in both groups. The only difference between the groups was a trend towards a better effect on sleep disturbances in the amitriptyline group. Side-effects were recorded more frequently in the amitriptyline group than in the citalopram group, global assessment of side effects being significantly different in favour of citalopram. It is concluded that citalopram is an effective and safe drug in the treatment of endogenous depression - probably as efficacious as amitriptyline, but with fewer side effects.     

西酞普兰与文拉法辛治疗抑郁症的对照研究

目的:比较西酞普兰与文拉法辛治疗抑郁症的疗效及安全性.方法:将50例抑郁症患者随机分入两组分别用西酞普兰和文拉法辛治疗,疗程6周,用汉密尔顿抑郁量表(HAMD)评定临床疗效,副反应量表(TESS)评定不良反应.结果:西酞普兰组显效率64.0%,有效率88.0%,文拉法辛组为60.0%,80.0%,两组疗效相仿.在治疗2周末时,文拉法辛组减分多于西酞普兰组,差异有显著性.两组不良反应均轻微.结论:西酞普兰和文拉法辛抗抑郁疗效肯定,不良反应轻.     

西酞普兰与马普替林治疗抑郁症对照研究

目的：探讨西酞普兰治疗抑郁症的疗效和安全性。方法：将60例抑郁症患者随机分为西酞普兰组和马普替林组,治疗6周。采用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）评定疗效,采用副反应量表（TESS）评定不良反应。结果：西酞普兰组显效率为83．3％,马普替林组显效率为76．7％,两组差异无显著性。HAMA减分率西酞普兰组明显多于马普替林组,西酞普兰组不良反应较少而轻微。结论：西酞普兰治疗抑郁症见效快,疗效肯定,不良反应轻,依从性好。     

Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice

The enhanced sensitivity of the elderly to the side effects produced by tricyclic antidepressants (TCAs), and the frequency and type of adverse events, have made the treatment of depression in this group difficult. The selective serotonin reuptake inhibitors (SSRIs) have been reported to produce significantly fewer undesirable side effects and display better tolerance than TCAs. We compared the therapeutic actions and side effects produced by citalopram, the most selective SSRI available, with amitriptyline in a group of elderly patients (aged 65 and older) diagnosed with major depression. In a double-blind, double-dummy, parallel-group, multicenter comparison of citalopram (20 or 40 mg/day) and amitriptyline (50 or 100 mg/day), patients who did not respond to placebo during a 1-week single-blind phase were randomly assigned to receive citalopram or amitriptyline for 8 weeks. Efficacy measures included the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Scale (HAMD), and Clinical Global Impressions. Both drug treatments produced equivalent time-related declines in severity of depression, so that by 8 weeks slightly more than 50% of the patients in each group experienced marked recovery, defined as MADRS scores ≤ 12. Amitriptyline produced a greater overall incidence of adverse events, including a significantly higher (P < 0.001) percentage of patients reporting dry mouth (34% vs. 7%), as well as a significantly higher (P < 0.02) incidence of somnolence. Constipation and fatigue also occurred more frequently in the amitriptyline than in the citalopram group. For only one event (nausea) did the citalopram group report a significantly greater (P = 0.012) incidence (12.8% vs. 4.8%). On the basis of these results, it was concluded that citalopram is as effective an antidepressant as amitriptyline in the treatment of the depressed elderly. Because of its low incidence and low magnitude of side effects, citalopram seems especially useful in private practice. Depression and Anxiety 8:147–153, 1998. © 1998 Wiley-Liss, Inc.     

西酞普兰与帕罗西汀治疗抑郁症对照研究

目的:比较西酞普兰与帕罗西汀治疗抑郁症的临床疗效和安全性. 方法:将68例符合中国精神障碍分类与诊断标准第3版抑郁发作诊断标准的患者,随机分为西酞普兰组与帕罗西汀组,疗程6周.用汉密尔顿抑郁量表(HAMD)评定疗效,用副反应量表(TESS)评定不良反应. 结果:西酞普兰组和帕罗西汀组的有效率分别为85.3%和82.4%,两组相仿.但治疗1周及2周后,西酞普兰组的有效率高于帕罗西汀组.两组间不良反应比较差异无显著性. 结论:西酞普兰是一种起效较快,且安全、有效的新型抗抑郁药.     

西酞普兰与氟西汀治疗抑郁症双盲对照研究

目的:探讨西酞普兰和氟西汀治疗首发抑郁症的疗效和安全性。方法:72例首发抑郁症患者随机以西酞普兰或氟西汀双盲治疗6周。结果:西酞普兰和氟西汀均具有良好的抗抑郁作用,疗效差异无显著性(P>0.05)。结论:西酞普兰治疗抑郁症安全有效。     

度洛西汀与西酞普兰治疗抑郁症的对照研究

目的:比较度洛西汀与西酞普兰治疗不同症状抑郁症的疗效.方法:将122例符合国际疾病分类第10版抑郁症诊断标准的患者,按不同主诉(精神症状或躯体症状)分为精神症状组60例和躯体症状组62例,每组再随机分为度洛西汀组(30例/30例)和西酞普兰组(30例/32例),分别给予度洛西汀和西酞普兰治疗6周.用汉密尔顿抑郁量表17...